UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038809
Receipt number R000042664
Scientific Title Phase I trial of ADR-002K for patients with ischemic cardiomyopathy who undergo coronary artery bypass surgery
Date of disclosure of the study information 2019/12/06
Last modified on 2022/11/29 06:56:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I trial of ADR-002K for patients with ischemic cardiomyopathy who undergo coronary artery bypass surgery

Acronym

Phase I trial of ADR-002K for patients with ischemic cardiomyopathy who undergo coronary artery bypass surgery

Scientific Title

Phase I trial of ADR-002K for patients with ischemic cardiomyopathy who undergo coronary artery bypass surgery

Scientific Title:Acronym

Phase I trial of ADR-002K for patients with ischemic cardiomyopathy who undergo coronary artery bypass surgery

Region

Japan


Condition

Condition

Ischemic Cardiomyopathy

Classification by specialty

Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Examination of following points of ADR-002K for patients with ischemic cardiomyopathy undergoing coronary artery bypass surgery
1)Safety
2)Efficacy (exploratory)
3)Feasibility

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

1) Adverse event and safety evaluation related to this product
2) Efficacy(exploratory)
3) Feasibility

Key secondary outcomes

1) Cardiac function
2) Exercise tolerance
3) Other


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

Bypass surgery and test product administration

Interventions/Control_2

Bypass surgery and placebo administration

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1) Patients who are clinically diagnosed with ischemic cardiomyopathy and receive CABG
2) Patients with a left ventricular ejection fraction of 40% or less by cardiac ultrasonography within 4 weeks before obtaining consent
3) Others

Key exclusion criteria

1) Patients who have a combination of cardiovascular disease such as severe organic valvular disease or aortic aneurysm determined by investigator or co-investigator to affect clinical trial procedure
2) Patients whose participation in a clinical trial is considered inappropriate at the discretion of the investigator or co-investigator
3) Others

Target sample size

6


Research contact person

Name of lead principal investigator

1st name Yoshiki
Middle name
Last name SAWA

Organization

Osaka University Hospital

Division name

Department of Cardiovascular Surgery

Zip code

565-0871

Address

2-15, Yamadaoka, Suita city

TEL

06-6879-3154

Email

sawa-p@surg1.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name MORI

Organization

Osaka University Hospital

Division name

Department of Cardiovascular Surgery

Zip code

565-0871

Address

2-15, Yamadaoka, Suita city

TEL

06-6879-3154

Homepage URL


Email

d-mori@surg1.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University Hospital

Institute

Department

Personal name



Funding Source

Organization

Osaka University Hospital
Rohto Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Osaka University Hospital

Address

2-2, Yamadaoka, Suita city

Tel

06-6210-8290

Email

jim-chiken@hp-crc.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 10 Month 27 Day

Date of IRB

2019 Year 09 Month 10 Day

Anticipated trial start date

2019 Year 11 Month 01 Day

Last follow-up date

2021 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The first case has been incorporated.


Management information

Registered date

2019 Year 12 Month 06 Day

Last modified on

2022 Year 11 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042664


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name